• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    TD Cowen initiated coverage on Reata Pharmaceuticals with a new price target

    7/6/23 7:38:38 AM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RETA alert in real time by email
    TD Cowen initiated coverage of Reata Pharmaceuticals with a rating of Outperform and set a new price target of $140.00
    Get the next $RETA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RETA

    DatePrice TargetRatingAnalyst
    7/6/2023$140.00Outperform
    TD Cowen
    6/12/2023$80.00 → $115.00Market Perform → Outperform
    SVB Securities
    10/19/2022$75.00Buy
    Guggenheim
    3/24/2022$91.00Buy
    Goldman
    3/1/2022$39.00 → $34.00Neutral
    Goldman Sachs
    12/9/2021$39.00Buy → Neutral
    Goldman Sachs
    12/9/2021$110.00 → $37.00Outperform → Neutral
    Robert W. Baird
    12/9/2021$112.00 → $68.00Overweight
    Cantor Fitzgerald
    More analyst ratings